LLY

903.18

+0.64%↑

UNH

602.1

+1.59%↑

JNJ

167.67

+0.57%↑

ABBV

197.99

+1.16%↑

MRK

115.03

-0.99%↓

LLY

903.18

+0.64%↑

UNH

602.1

+1.59%↑

JNJ

167.67

+0.57%↑

ABBV

197.99

+1.16%↑

MRK

115.03

-0.99%↓

LLY

903.18

+0.64%↑

UNH

602.1

+1.59%↑

JNJ

167.67

+0.57%↑

ABBV

197.99

+1.16%↑

MRK

115.03

-0.99%↓

LLY

903.18

+0.64%↑

UNH

602.1

+1.59%↑

JNJ

167.67

+0.57%↑

ABBV

197.99

+1.16%↑

MRK

115.03

-0.99%↓

LLY

903.18

+0.64%↑

UNH

602.1

+1.59%↑

JNJ

167.67

+0.57%↑

ABBV

197.99

+1.16%↑

MRK

115.03

-0.99%↓

Home・Listă Acțiuni・Novo Nordisk A-S

Novo Nordisk A-S

Închisă

Sector Sănătate

128.68 -2.19

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

128.78

Maxim

132.02

Indicatori cheie
By Trading Economics
Venit	-5.4B 20B
Vânzări	2.7B 68B
P/E Medie Sector	49.94 103.001
EPS	4.49
Marjă de profit	29.459
EBITDA	-1.2B 36B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+7.42 upside

Statistici piață
By TradingEconomics
Capitalizare de piață	711M 471B
Deschiderea anterioară	130.87
Închiderea anterioară	128.68

Sentimentul știrilor

By Acuity

50%

115 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

130.53 / 134.62 Suport & Rezistență

Novo Nordisk A-S Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 aug. 2024, 10:13 UTC

Câștiguri

Novo Nordisk's Wegovy Sales Disappoint -- 2nd Update

7 aug. 2024, 06:58 UTC

Câștiguri

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge -- Update

7 aug. 2024, 06:10 UTC

Câștiguri

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge

9 sept. 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3 sept. 2024, 11:09 UTC

Top știri

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27 aug. 2024, 05:30 UTC

Top știri

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14 aug. 2024, 12:01 UTC

Market Talk

Câștiguri

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9 aug. 2024, 11:30 UTC

Top știri

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9 aug. 2024, 07:30 UTC

Market Talk

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8 aug. 2024, 15:44 UTC

Top știri

Câștiguri

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

8 aug. 2024, 11:36 UTC

Market Talk

Câștiguri

Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk

8 aug. 2024, 07:16 UTC

Market Talk

Câștiguri

Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk

7 aug. 2024, 20:30 UTC

Top știri

Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here's What to Expect. -- Barrons.com

7 aug. 2024, 16:39 UTC

Câștiguri

Novo Nordisk's Wegovy Sales Disappoint -- Update

7 aug. 2024, 15:30 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Novo Nordisk's Wegovy Sales Disappoint -- WSJ

7 aug. 2024, 14:22 UTC

Top știri

Câștiguri

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7 aug. 2024, 12:28 UTC

Market Talk

Câștiguri

Novo Nordisk's Core Products Disappoint -- Market Talk

7 aug. 2024, 12:04 UTC

Câștiguri

Novo Nordisk Execs Were Speaking on a Call After 2Q Earnings

7 aug. 2024, 11:34 UTC

Câștiguri

Novo Nordisk US Head: As Wegovy Volumes Go Up, Prices Will Come Down

7 aug. 2024, 11:34 UTC

Câștiguri

Novo Nordisk CEO: When You Move Into New Sales Channels it Comes With a Discount

7 aug. 2024, 11:34 UTC

Câștiguri

Novo Nordisk CEO: Wegovy Now Covered in 20 States Through Medicaid

7 aug. 2024, 11:05 UTC

Market Talk

Câștiguri

Novo Nordisk Delivers Messy Quarter as Wegovy Misses The Mark -- Market Talk

7 aug. 2024, 10:55 UTC

Câștiguri

Stock Market Madness Highlights This Problem for -2-

7 aug. 2024, 10:55 UTC

Câștiguri

Stock Market Madness Highlights This Problem for Novo Nordisk and Super Micro. And 5 Other Things to Know Today. -- Barrons.com

7 aug. 2024, 09:07 UTC

Câștiguri

Acțiuni populare

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7 aug. 2024, 08:55 UTC

Top știri

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

7 aug. 2024, 07:32 UTC

Market Talk

Câștiguri

Novo Nordisk Wegovy Sales Disappoint -- Market Talk

7 aug. 2024, 05:45 UTC

Câștiguri

Novo Nordisk Declares Interim Dividend of DKK3.50

7 aug. 2024, 05:44 UTC

Câștiguri

Novo Nordisk 2Q Gross Margin 84.9% Vs 85.5%, Op Margin 38.1% Vs 44.0%

7 aug. 2024, 05:40 UTC

Câștiguri

Novo Nordisk 2Q Wegovy Drug Sales DKK11.66B Vs DKK7.52B

Comparație

Modificare preț

Novo Nordisk A-S Așteptări

Obiectiv de preț

By TipRanks

7.42% sus

Prognoză pe 12 luni

Medie 141.7 USD 7.42%

Maxim 166 USD

Minim 82.5 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruNovo Nordisk A-S - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Novo Nordisk A-S - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

130.53 / 134.62Suport & Rezistență

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

115 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

EBITDA

Profit operațional

Despre Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.